Comparable efficacies of the antimicrobial peptide human lactoferrin 1-11 and gentamicin in a chronic methicillin-resistant Staphylococcus aureus osteomyelitis model

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 6, 2005, Pages 2438-2444

  Faber, Christopher ^a,b   Stallmann, Hein P ^a,b   Lyaruu, D M ^b   Joosten, Uwe ^c   Von Eiff, Christof ^d   Van Nieuw Amerongen, Arie ^b   Wuisman, Paul I J M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c MarienHospital Osnabruck   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BONE CEMENT; CALCIUM PHOSPHATE; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; GLYCOPEPTIDE; HUMAN LACTOFERRIN[1-11]; LACTOFERRIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BONE RADIOGRAPHY; CONTROLLED STUDY; DISEASE MODEL; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; HISTOLOGY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; OSTEOMYELITIS; PRIORITY JOURNAL; RABBIT; SCORING SYSTEM; TIBIA;

ANIMALS; ANTI-BACTERIAL AGENTS; BONE CEMENTS; CALCIUM PHOSPHATES; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; GENTAMICINS; HUMANS; METHICILLIN RESISTANCE; OSTEOMYELITIS; PEPTIDE FRAGMENTS; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TIBIA; TREATMENT OUTCOME;

EID: 19544368472     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.6.2438-2444.2005     Document Type: Article

References (31)

1. Castro, C., E. Sanchez, A. Delgado, I. Soriano, P. Nunez, M. Baro, A. Perera, and C. Evora. 2003. Ciprofloxacin implants for bone infection. In vitro-in vivo characterization. J. Control. Release 93:341-354.
2. Craig, W. A. 1995. Once-daily versus multiple-daily dosing of aminoglycosides. J. Chemother. 7(Suppl. 2):47-52.
3. Giacometti, A., O. Cirioni, R. Ghiselli, F. Mocchegiani, M. S. Del Prete, C. Viticchi, W. Kamysz, E. LEmpicka, V. Saba, and G. Scalise. 2002. Potential therapeutic role of cationic peptides in three experimental models of septic shock. Antimicrob. Agents Chemother. 46:2132-2136.
4. Hancock, R. E. 1997. Peptide antibiotics. Lancet 349:418-422.
5. Hill, J., L. Klenerman, S. Trustey, and R. Blowers. 1977. Diffusion of antibiotics from acrylic bone-cement in vitro. J. Bone Joint Surg. Br. 59:197-199.
6. Ichiyama, S., M. Ohta, K. Shimokata, N. Kato, and J. Takeuchi. 1991. Genomic DNA fingerprinting by pulsed-field gel electrophoresis as an epidemiological marker for study of nosocomial infections caused by methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 29:2690-2695.
7. Jenny, G. 1988. Local antibiotic therapy using gentamicin-PMMA chains in posttraumatic bone infections. Short and long-term results. Reconstr. Surg. Traumatol. 20:36-46.
8. Kac, G., A. Buu-Hoi, E. Herisson, P. Biancardini, and C. Debure. 2000. Methicillin-resistant Staphylococcus aureus. Nosocomial acquisition and carrier state in a wound care center. Arch. Dermatol. 136:735-739.
9. Kanellakopoulou, K., and E. J. Giamarellos-Bourboulis. 2000. Carrier systems for the local delivery of antibiotics in bone infections. Drugs 59:1223-1232.
10. Levin, M., P. A. Quint, B. Goldstein, P. Barton, J. S. Bradley, S. D. Shemie, T. Yeh, S. S. Kim, D. P. Cafaro, P. J. Scannen, and B. P. Giroir. 2000. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 356:961-967.
11. Lupetti, A., A. Paulusma-Annema, M. M. Welling, H. Dogterom-Ballering, C. P. Brouwer, S. Senesi, J. T. Van Dissel, and P. H. Nibbering. 2003. Synergistic activity of the N-terminal peptide of human lactoferrin and fluconazole against Candida species. Antimicrob. Agents Chemother. 47:262-267.
12. Lupetti, A., A. Paulusma-Annema, M. M. Welling, S. Senesi, J. T. Van Dissel, and P. H. Nibbering. 2000. Candidacidal activities of human lactoferrin peptides derived from the N terminus. Antimicrob. Agents Chemother. 44:3257-3263.
13. Marks, K. E., C. L. Nelson, and E. P. Lautenschlager. 1976. Antibiotic-impregnated acrylic bone cement. J. Bone Joint Surg. Am. 58:358-364.
14. Neut, D., H. van de Belt, I. Stokroos, J. R. van Horn, H. C. van der Mei, and H. J. Busscher. 2001. Biomaterial-associated infection of gentamicin-loaded PMMA beads in orthopaedic revision surgery. J. Antimicrob. Chemother. 47:885-891.
15. Neut, D., H. van de Belt, J. R. van Horn, H. C. van der Mei, and H. J. Busscher. 2003. Residual gentamicin-release from antibiotic-loaded polymethylmethacrylate beads after 5 years of implantation. Biomaterials 24:1829-1831.
16. Nibbering, P. H., E. Ravensbergen, M. M. Welling, L. A. van Berkel, P. H. van Berkel, E. K. Pauwels, and J. H. Nuijens. 2001. Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infect. Immun. 69:1469-1476.
17. Norden, C. W. 1988. Lessons learned from animal models of osteomyelitis. Rev. Infect. Dis. 10:103-110.
18. Norden, C. W., R. L. Myerowitz, and E. Keleti. 1980. Experimental osteomyelitis due to Staphylococcus aureus or Pseudomonas aeruginosa: a radiographic-pathological correlative analysis. Br J. Exp. Pathol. 61:451-460.
19. Ooms, E. M., J. G. Wolke, J. P. van der Waerden, and J. A. Jansen. 2002. Trabecular bone response to injectable calcium phosphate (Ca-P) cement. J. Biomed. Mater. Res. 61:9-18.
20. Smeltzer, M. S., J. R. Thomas, S. G. Hickmon, R. A. Skinner, C. L. Nelson, D. Griffith, T. R. Parr, and R. P. Evans. 1997. Characterization of a rabbit model of staphylococcal osteomyelitis. J. Orthop. Res. 15:414-421.
21. Stallmann, H. P., C. Faber, A. L. Bronckers, A. V. Nieuw Amerongen, and P. I. Wuisman. 2004. Osteomyelitis prevention in rabbits using antimicrobial peptide hLF1-11- or gentamicin-containing calcium phosphate cement. J. Antimicrob. Chemother. 54:472-476.
22. Stallmann, H. P., C. Faber, E. T. Slotema, D. M. Lyaruu, A. L. Bronckers, A. van Nieuw Amerongen, and P. I. Wuisman. 2003. Continuous-release or burst-release of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11) from calcium phosphate bone substitutes. J. Antimicrob. Chemother. 52: 853-855.
23. van de Belt, H., D. Neut, J. R. van Horn, H. C. van der Mei, W. Schenk, and H. J. Busscher. 1999. Or not to treat? Nat. Med. 5:358-359.
24. van't Hof, W, E. C. Veerman, E. J. Helmerhorst, and A. V. Nieuw Amerongen. 2001. Antimicrobial peptides: properties and applicability. Biol. Chem. 382:597-619.
25. von Eilf, C., D. Bettin, R. A. Proctor, B. Rolauffs, N. Lindner, W. Winkelmann, and G. Peters. 1997. Recovery of small colony variants of Staphylococcus aureus following gentamicin bead placement for osteomyelitis. Clin. Infect. Dis. 25:1250-1251.
26. Wahlig, H., E. Dingeldein, R. Bergmann, and K. Reuss. 1978. The release of gentamicin from polymethylmethacrylate beads. An experimental and pharmacokinetic study. J. Bone Joint Surg. Br. 60B:270-275.
27. Walenkamp, G. H. 2001. Gentamicin PMMA beads and other local antibiotic carriers in two-stage revision of total knee infection: a review. J. Chemother. Spec No. 13:66-72.
28. Walenkamp, G. H., L. L. Kleijn, and M. de Leeuw. 1998. Osteomyelitis treated with gentamicin-PMMA beads: 100 patients followed for 1-12 years. Acta Orthop. Scand. 69:518-522.
29. Whitener, C. J., S. Y. Park, F. A. Browne, L. J. Parent, K. Julian, B. Bozdogan, P. C. Appelbaum, J. Chaitram, L. M. Weigel, J. Jernigan, L. K. McDougal, F. C. Tenover, and S. K. Fridkin. 2004. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Clin. Infect. Dis. 38:1049-1055.
30. Witte, W. 1999. Antibiotic resistance in gram-positive bacteria: epidemiological aspects. J. Antimicrob. Chemother. 44(Suppl. A):1-9.
31. Zasloff, M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415:389-395.